Company Overview
Nutriband Inc. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it develops a portfolio of transdermal pharmaceutical products for the United States market. The company's primary operational focus is the advancement of AVERSA fentanyl, a lead product in development designed as an abuse deterrent fentanyl transdermal system that offers clinicians and patients an extended-release transdermal fentanyl option. In terms of scale, the company holds a market capitalization of $47.00M and reported annual revenue of $2.28M over the trailing twelve months, while the specific count of employees is not publicly disclosed in available data. These valuation and revenue figures indicate that Nutriband Inc. functions as a small-cap biotechnology entity with limited revenue generation relative to its market cap, suggesting a capital-intensive business model typical of firms in early-stage clinical development that rely heavily on future product approvals to realize profitability.
Financial Health
The company reported a revenue of $2.28M for the trailing twelve months, yet this top-line figure stands in stark contrast to a net income of $-34,592,176, revealing a significant gap that highlights a highly aggressive cost structure or substantial research and development expenses consuming all operating profits. Additionally, the company recorded an EBITDA of $-9,029,840 and generated free cash flow of $-2,588,350, which indicates a negative cash generation profile where operating activities and investing activities combined are depleting the company's liquidity reserves. When analyzing profitability margins, the gross margin stands at 33.5%, suggesting that the cost of goods sold consumes roughly two-thirds of sales, while the operating margin of -1121.3% and profit margin of 0.0% demonstrate severe operational inefficiencies or massive period costs not yet reflected in the bottom line. Regarding the balance sheet, the company holds $5.31M in cash against $258,025 in debt, resulting in a debt-to-equity ratio of 3.42, which implies a leveraged position where equity is significantly diluted relative to liabilities despite the low absolute debt figure. The current ratio is reported at 7.53, indicating a robust ability to cover short-term liabilities with short-term assets, although this high ratio in a cash-burning company may reflect an accumulation of assets rather than efficient working capital management. Return on Equity stands at -136.1% and Return on Assets is -55.2%, metrics that reveal management is currently destroying value per unit of capital invested rather than generating returns, a common characteristic for biotech firms before their lead assets reach commercialization.
Valuation Assessment
The trailing P/E ratio is not applicable due to negative earnings, while the forward P/E is listed at -16.78, a metric that implies analysts or the market expects earnings to remain negative in the near term or that the current price does not reflect any anticipated positive earnings trajectory. The price-to-book ratio is 6.22, indicating that the market values the company at more than six times its net asset value, which suggests a significant market premium over book value often seen in biotechnology firms betting on the potential of their intellectual property pipeline. Alternative valuation metrics show a price-to-sales ratio of 20.63 and an EV/EBITDA of -4.64, suggesting that the company is being valued based on revenue multiples rather than profitability, a standard practice for pre-revenue or loss-making pharmaceutical companies where future cash flows are the primary value driver. Price metrics show a 52-week high of $11.68 and a 52-week low of $3.42, placing the current trading environment within a wide range that reflects high volatility common in small-cap biotech stocks. The beta value is 1.88, which means the stock is expected to be nearly twice as volatile as the broader market, exposing investors to significant price swings that correlate with sector-specific events rather than general market movements.
Growth & Income
The company experienced a revenue growth of -46.4% year-over year, while earnings growth is not applicable due to losses, implying that the business is contracting or that revenue recognition patterns are shifting as the company navigates its development phase. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, all available capital must be reinvested into growth initiatives such as clinical trials and regulatory submissions rather than being distributed to shareholders. The negative revenue growth combined with substantial net losses indicates that the company is in a capital expenditure-heavy phase where revenue cannot yet cover the costs of bringing the AVERSA fentanyl product to market. Overall, the growth and income profile is characterized by significant revenue contraction and a complete reliance on external capital or cash reserves to fund operations until the lead product achieves commercial success.